Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 13/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026258 | 0.90 | EGFR (0.64) | ALKMETEGFRHDAC6IRAK4 | |
| SCHEMBL29937318 | 0.90 | EGFR (0.64) | ALKMETEGFRHDAC6IRAK4 | |
| SCHEMBL29313605 | 0.88 | ALK (0.60) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL21026264 | 0.79 | EGFR (0.71) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL29937745 | 0.79 | EGFR (0.71) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL21025772 | 0.79 | EGFR (0.71) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL1925640 | 0.79 | EGFR (0.66) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL29937945 | 0.79 | EGFR (0.66) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL13500557 | 0.79 | EGFR (0.66) | ALKMETEGFRIRAK4MAP3K7 | |
| SCHEMBL1925637 | 0.79 | EGFR (0.66) | ALKMETEGFRIRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALK 746/4885MET 234/4885EGFR 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.